Receptors, Cell Surface

Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
DrugDrug NameDrug Indication
DB00005EtanerceptEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.
DB05332RomiplostimTreatment of chronic immune thrombocytopenic purpura.
DB05777Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
DB06495OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
DB06511AMGN-0007Investigated for use/treatment in osteoporosis and bone metastases.
DB06611PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DB08885AfliberceptThe opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
DB14988DalanterceptNot Available
DB15045IpafriceptNot Available
DB15160AsunerceptNot Available
DB15386ALT-801Not Available
DB13881TisagenlecleucelIndicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse [FDA Label].